In fact, in a murine melanoma model, disruption of vascular endothelial growth factor/VEGF receptor‐2 (VEGF/VEGFR‐2) signaling by treatment with anti‐VEGF showed a synergistic efficiency with an immunotherapy employing adoptively transferred T cells carrying a transgenic TCR directed to a melanoma antigen, resulting in enhanced tumor tissue infiltration.80 Here, VEGFA is linked to melanoma.